Neoadjuvant paradigm for accelerated drug development: an ideal model in bladder cancer. - Wikidata - awgldk - TriplyDB

Neoadjuvant paradigm for accelerated drug development: an ideal model in bladder cancer.

Neoadjuvant paradigm for accelerated drug development: an ideal model in bladder cancer.

http://www.wikidata.org/entity/Q37128756

about

Perioperative and Maintenance Therapy After First-Line Therapy as Paradigms for Drug Discovery in Urothelial Carcinoma Systemic, perioperative management of muscle-invasive bladder cancer and future horizons.Optimizing care and outcomes of patients with muscle-invasive bladder cancer.Invasive bladder cancer: ignoring the data.

P2860

Q27024948-06AEF695-E98A-46C5-A05C-535762B6EFF8 Q30240816-3F05081E-86CB-417E-A231-56E482E2839B Q37455252-1497BE76-0F99-42C8-84CA-4D2B70C2F23C Q42575248-3DAE964E-782F-4908-B84E-76E250A54D52

P2860

Neoadjuvant paradigm for accelerated drug development: an ideal model in bladder cancer.

http://www.wikidata.org/entity/Q37128756

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 24 July 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Neoadjuvant paradigm for accelerated drug development: an ideal model in bladder cancer.

@en

Neoadjuvant paradigm for accelerated drug development: an ideal model in bladder cancer.

@nl

type

label

Neoadjuvant paradigm for accelerated drug development: an ideal model in bladder cancer.

@en

Neoadjuvant paradigm for accelerated drug development: an ideal model in bladder cancer.

@nl

prefLabel

Neoadjuvant paradigm for accelerated drug development: an ideal model in bladder cancer.

@en

Neoadjuvant paradigm for accelerated drug development: an ideal model in bladder cancer.

@nl

P1433

Q37128756-46D3521F-9006-4815-A635-26E6085D16C0

P1476

Q37128756-007F71CD-1155-406F-BF57-8FC0F4E12102

P2093

Q37128756-0CC685B9-D3F8-456B-84B0-92AB924D935C

Q37128756-277E9A44-F25C-4AF3-AE91-24BBCF40E06A

Q37128756-724D04A4-B584-4E3E-BAB2-C246B71FB711

P2860

Q37128756-05A2347B-D677-44F3-B1B4-298BDACED1BC

Q37128756-0A002527-687A-4E06-A09E-42E4E3D9124A

Q37128756-0C673618-1D13-43A6-915C-515AAC4A59E2

Q37128756-0C807C3B-4A9B-4A90-A20F-3E50784FFB2D

Q37128756-10567686-2988-430F-B2AD-31C6FC2ACFC6

Q37128756-14EE9710-6797-41A6-AF25-A02C16909F03

Q37128756-1528F061-7897-4433-A405-BCEE5E21D601

Q37128756-16CE5F68-E1F4-4A2D-ACF9-4FA4DFF476C2

Q37128756-196FE91B-688A-4DB1-B7CB-5702685B1E6A

Q37128756-1AEADB30-F788-4731-B152-B5D764B80D92

P304

Q37128756-46ADF4FD-8C86-434E-AB59-88ACFB574BE9

P31

Q37128756-4DFC8373-43D2-4654-B029-579985A64FA5

P356

Q37128756-9BA699BE-D300-455B-9190-0552738E135E

P433

Q37128756-A3039E81-1F83-4A9C-A9A5-2EF0DB1664E1

P478

Q37128756-B8ECC3C2-AA92-43F5-AFDA-FD192E43FFD9

P577

Q37128756-5901F2CF-E331-495C-8B81-D6A00213DFA9

P698

Q37128756-37B51FE6-03C6-4224-B009-182D5D1530D5

P932

Q37128756-3C822E8B-E551-4EB9-B2DA-D3F843E62BB5

P356

THEONCOLOGIST.2013-0023

P1433

P1476

Neoadjuvant paradigm for accelerated drug development: an ideal model in bladder cancer.

@en

P2093

David D Chism

http://www.w3.org/2001/XMLSchema#string

Matthew I Milowsky

http://www.w3.org/2001/XMLSchema#string

Michael E Woods

http://www.w3.org/2001/XMLSchema#string

P2860

Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials

Genome sequencing identifies a basis for everolimus sensitivity

Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study.

Cancer statistics, 2012

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

Integrating perioperative chemotherapy into the treatment of muscle-invasive bladder cancer: strategy versus reality.

The COXEN principle: translating signatures of in vitro chemosensitivity into tools for clinical outcome prediction and drug discovery in cancer.

A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery

P304

933-940

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1634/THEONCOLOGIST.2013-0023

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P577

2013-07-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23883869

http://www.w3.org/2001/XMLSchema#string

P932

3755931

http://www.w3.org/2001/XMLSchema#string